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Abstract
Background: Pharmacy interventions are a subset of public health interventions and its research is usually performed
within the scope of a trial. The economic evaluation of pharmacy interventions requires certain considerations which
have some similarities to those of public health interventions and to economic evaluations alongside trials. The
objective of this research is to perform an overview of systematic reviews of economic evaluations of pharmacy
services and triangulate results with recommendations for economic evaluations of both public health interventions
and alongside trials.
Methods: (1) Exploratory review of recommendations on the economic evaluation of public health interventions, (2)
exploratory review of recommendations for conducting economic evaluations alongside trials, (3) overview of
systematic reviews of economic evaluations of pharmacy interventions (protocol registered with PROSPERO 2016
outlining information sources, inclusion criteria, appraisal of reviews and synthesis methods).
Results: Fourteen systematic reviews containing 75 index publications were included. Reviews reported favorable
economic findings for 71% of studies with full economic evaluations. The types of economic analysis are diverse. Two
critical quality domains are absent from most reviews. Key findings include the following: certain types of risk of bias,
wider scope of study designs, and most economic quality criteria met but some issues unresolved or unclear.
Triangulation revealed additional gaps. Limitations include choice of critical quality domains and potential biases in the
overview process.
Conclusions: Economic evaluations of pharmacy-based public health interventions seem to follow most economic
quality criteria, but there are still some issues in certain key areas to improve. These findings may assist in improving
the design of pilot trials of economic evaluations in pharmacy, leading to robust evidence for payers. Based on the
findings, we propose a methodological approach for the economic evaluation of pharmacy-based public health
interventions.
Systematic review registration: PROSPERO CRD42016032768
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Background
Pharmacy-based public health interventions can be
defined as complex health interventions, provided by
pharmacists to patients in the community pharmacy set-
ting, which are beyond, but do not necessarily exclude,
the medication supply role.
These interventions include health promotion and sup-
port on self-monitoring, disease prevention, screening,
and disease and medication management and cover a wide
spectrum of areas, including the main public health areas
of interest as defined by the National Institute for Health
and Care Excellence (NICE): cardiovascular disease;
chronic illness; diabetes; drugs; mental health; obesity;
physical activity; screening; sexual health; smoking and
tobacco; and vaccine preventable diseases [1], to name
only the more relevant.
Complex health interventions require several interact-
ing components, including behavioral changes from
providers and patients, factors influencing multiple
levels, and some degree of flexibility of interventions [2].
All these features have also been identified in pharmacy
interventions [3, 4].
The strategies used to operate pharmacy-based complex
health interventions at multiple levels seem to be consist-
ent with the diffusion of innovation theory [5]. At the
patient level, behavioral changes seem to be consistent
with the theory of planned behavior [6] for screening; the
information-motivational-behavioral skills model for
medication adherence [7]; and social cognitive theory, the
transtheoretical model, and the theory of planned behav-
ior for disease management [8]. Behavior changes in phar-
macists and in patients then lead to improved health
outcomes [4]. The conceptual logic framework, used by
Blalock et al., and a logic model, as per the Medical Re-
search Council (MRC), are interesting avenues to explore
[4, 9]. These interventions fall under the umbrella of pre-
vention interventions, as opposed to treatment interven-
tions. However, according to the Organization for
Economic Co-operation and Development (OECD), in
2010, only 3% of health budgets in the European Union
(EU) were spent on prevention, yet a good balance in fi-
nancing of treatment and prevention was found to be
cost-effective to improve health outcomes [10].
Financing prevention interventions requires economic
evaluations which should be a routine and consistent
part of all public health interventions [11], including
pharmacy-based public health interventions.
In fact, the original definition of pharmacoeconomics
clearly identified the description and analysis of the costs
and consequences of pharmacy services as a domain of
pharmacoeconomics [12]. However, the economic evalu-
ation of pharmacy services requires certain unique
considerations [13]. Many of these challenges seem to
involve comparators, selection bias, social interaction
threats, outcome measures, study design, effect of inter-
ventions, type of economic evaluation, and study site
[13, 14]. Some of these issues do not seem to be exclu-
sive to pharmacy; they also exist in public health inter-
ventions [15]. For instance, the Centers for Disease
Control and Prevention (CDC) and NICE have acknowl-
edged these major specificities [1, 16]. The MRC also
underlines that the economic evaluation is one of the
key components of the development and evaluation of
complex health interventions [2].
In addition, there are also methodological recommen-
dations for conducting economic evaluations alongside
clinical or pragmatic trials, which may be useful to
explore [17, 18].
The first economic evaluations of clinical pharmacy
services, a subset of public health interventions provided
by pharmacists to optimize medication therapy and
promote health, wellness, and disease prevention, were
published in the late 1970s. As the profession progressed
beyond dispensing, an increasing number of evaluations
were published [13].
A landmark economic study demonstrated the
important healthcare savings of medication manage-
ment services provided by pharmacists [19]. This
landmark study was still restricted to a clinical phar-
macy service. Later on, evidence of health outcome
improvements in broader public health interventions
provided by community pharmacists in appropriate
collaborative environments with physicians was estab-
lished [4, 20–22]. In the UK, the effectiveness and
cost-effectiveness of the contribution of community
pharmacy to improving public health has been estab-
lished for certain pharmacy interventions beyond
clinical pharmacy services [23].
Hence, the economic evaluation of such services in col-
laborative care environments may contribute to informing
decisions made regarding the successful expansion, con-
tinuation, or justification of such services [13].
The overall aim of this research is to perform an overview
of systematic reviews of economic evaluations of pharmacy
services to better understand their successes and downsides
and to assist in improving the methods for future research,
following the early work of Schumock [13, 14] and recent
important contributions by Elliott et al. [24], but focusing
on the community pharmacy setting.
Since the term “pharmacy services” is more frequently
used by researchers in pharmacy practice and the term
“public health interventions” is, however, used more
frequently in the context of health technology assess-
ment and economic evaluation, we will use the terms
pharmacy-based public health interventions and phar-
macy services interchangeably.
There are already a few systematic reviews on the eco-
nomic evaluation of pharmacy services, which support
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the rationale to conduct this overview of reviews. We
found two overviews of reviews on pharmacy services
[21, 22]. However, they address the question of effective-
ness and are not focused on methods.
This overview is, to the best of our knowledge, the first
centered on methods of economic evaluations exclu-
sively in the pharmacy setting and triangulating results
with recommendations for economic evaluations of
public health interventions and for economic evaluations
alongside trials.
Objectives
The objectives of this paper are as follows: to review the
methods and issues in systematic reviews of economic
evaluations of pharmacy services compared with usual
care or other alternatives in multiple population groups;
to compare these with recommendations on the eco-
nomic evaluation of public health interventions and
conducted alongside clinical and pragmatic trials; to
propose a system for the measurement and valuation of
costs and health effects feasible for the economic evalu-
ation studies of pharmacy services; and to contribute to
the methods in the economic evaluation of pharmacy
services and of public health interventions.
Methods
Exploratory review of recommendations on the economic
evaluation of public health interventions
We selected four policy documents that addressed the
specifics and issued recommendations on the economic
evaluation of public health interventions: Kelly et al.
[11], Honeycutt et al. [16], MRC [2], and NICE [1]. Six
academic papers were also selected: Cookson et al. [25],
Weatherly et al. [15], Lorgelly et al. [26], Marsh et al.
[27], Edwards et al. [28], and Alayli-Goebbels et al. [29].
This was a selected search on existing recommenda-
tions on the economic evaluation of public health
interventions with the purpose of obtaining key in-
sights for triangulation. This selected search was per-
formed on MEDLINE® (via PubMed) in titles/abstracts
till July 2017. A first search used the following terms
in titles/abstracts: “review” and “economic evaluation”
and “public health interventions” and “methods”
which returned 15 titles. After reviewing title and ab-
stract, we included five relevant articles [15, 25–28].
A second similar search was performed replacing
“public health interventions” for “behavior” and “inter-
ventions” which returned 22 titles of which, after
reviewing title and abstract, we selected one [29]. We
then performed snowballing from reference lists of
more recent included articles [28, 29] and further se-
lected four policy papers [1, 2, 11, 16].
Exploratory review of recommendations for conducting
economic evaluations alongside clinical or pragmatic
trials
We selected three academic publications that issued spe-
cific recommendations for conducting economic evalua-
tions alongside clinical or pragmatic trials: O’Sullivan
et al. [17], Petrou and Gray [18], and Ramsey et al. [30].
This was a selected search on existing recommenda-
tions on the economic evaluation alongside clinical or
pragmatic trials with the purpose of obtaining key
insights for triangulation. This selected search was first
performed on MEDLINE® (via PubMed) till July 2017
using the term “economic evaluation” in title/abstract
and the following terms in title: “alongside” and (“clinical
trials” or “randomized controlled trials”). This first
search returned 14 titles of which we just selected the
two most recent relevant titles available for free [17, 18].
We then performed a search on ISPOR website under
Good Practices for Outcomes Research on July 2017,
and we selected the most recent report on economic
evaluation alongside clinical trials [30].
Overview of systematic reviews of economic evaluations
of pharmacy interventions
This overview considered recommendations by Cochrane,
by Smith et al., and by the Joanna Briggs Institute (JBI)
[31–33] for overviews and by the Centre for Reviews and
Dissemination (CRD) of the University of York and
Cochrane for systematic reviews for public health inter-
ventions and for economic evaluations [34–36].
We have followed PRISMA Checklist in reporting this
overview. See supplementary completed PRISMA Check-
list, Additional file 1.
Protocol registration and eligibility criteria
The protocol of this overview was registered with the
International Prospective Register of Systematic Reviews
(PROSPERO) on 7 January 2016. Reference number
PROSPERO 2016: CRD42016032768 (http://www.crd.
york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016
032768). It outlines the methods for eligibility criteria,
information sources, search strategy, study selection, data
extraction, quality assessment, and strategy for data
synthesis. Conference abstracts (no full papers available)
and study protocols were excluded.
Reviews were included if they met the following in-
clusion criteria: systematic review as per stated by au-
thors or implied by methods; describing or containing
individual economic evaluation studies (economic
evaluation and/or equivalent terms “economic” OR
“economic evaluation” OR “cost-effectiveness” OR
“cost-utility” OR “cost-benefit” explicitly stated in
search terms of systematic review); describing
pharmacist-provided patient care interventions as per
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protocol definition published in PROSPERO (complex
public health interventions, in health promotion, dis-
ease prevention, and disease/medication management,
provided by pharmacists to patients in the community
pharmacy setting, with the aim of preventing disease,
promoting health, and prolonging life, which are be-
yond, but not necessarily excluding, the medication
supply role); and describing or containing at least one
economic study in community pharmacy setting.
No restriction on the types of populations, compara-
tors, nor outcomes was considered, as stated in protocol,
as this was an inclusive review to critique methods and
aid future research design.
Information sources
A comprehensive search was performed in the following
databases through July 2017: MEDLINE®In-Process &
Other Non-Indexed Citations, MEDLINE® (from 1946)
and EMBASE (from 1980), via the OVID SP interface;
Cochrane Database of Systematic Reviews (CDSR);
Database of Abstracts of Reviews of Effects (DARE),
NHS Economic Evaluation Database (NHS EED) and
HTA, via the CRD database; Tufts CEA Registry; and
Web of Science to identify existing systematic reviews of
economic evaluation studies of pharmacy services.
In addition, a further search was performed in Google
Scholar and snowballing from reference lists of retrieved
reviews. An additional search for gray literature was
performed in the ISPOR Database and OpenGrey.
Finally, a search for ongoing systematic reviews was
performed in PROSPERO.
Search
Searches used the following terms: “systematic review” and
“economic evaluation” (or “cost-effectiveness” or “cost-util-
ity” or “cost-benefit”) and “pharmacy” (or “pharmacist”)
and “intervention” (or “service” or “program” or “manage-
ment”) with slight changes, according to the conventions of
each database, in combination with database-specific filters
for systematic reviews and economic evaluations.
See supplementary detailed search strategies,
Additional file 2.
Selection of reviews
Citations that resulted from searches were downloaded,
and duplicates were removed. Two researchers (SC and
MC) reviewed all potentially relevant titles against the
inclusion criteria and reviewed the abstracts associated
with retrieved titles. Finally, full-text articles of retrieved
abstracts were reviewed for eligibility by two review
team members (SC and CM). Disagreements were re-
solved through discussion with additional review team
members (CM and DKH). We recorded the reasons for
exclusion at screening.
See supplementary list of excluded reviews,
Additional file 3.
We have followed the PRISMA flowchart in reporting
the study selection [37].
Data collection process
A template adapted from the JBI Data Extraction Form
for Reviews of Systematic Reviews [33] was developed
and prepiloted to assist with data extraction.
Extracted data (SC) of eight randomly selected reviews
were audited by two other review team members (CM
and DKH). Existing discrepancies were resolved through
discussion. None of the review team members was blind
to journal titles or to study authors or institutions.
Since primary studies are often included in more than
one review, the degree of overlap was determined using
the corrected covered area (CCA) method of Pieper et al.
A CCA value lower than 5% is a slight overlap [38].
Data items
The following items were extracted: title; first author/
year of publication; journal; objectives; no. and sources
searched; date range of reviews; no. of included eco-
nomic evaluation community pharmacy (CP) studies/
total no. of studies; countries of origin of CP studies;
populations in CP studies; interventions in CP studies;
comparators in CP studies; outcomes in CP studies;
study designs in CP studies; types of economic evalu-
ation in CP studies/total; cost and resource use categor-
ies in CP studies; cost year/discount rates in CP studies;
data sources in CP studies; perspectives in CP studies;
key findings in CP studies; uncertainty in included
studies; assessment of quality of evidence for deriving
effectiveness; assessment of risk of bias; assessment of
economic quality; method of data synthesis; key findings
of SR; significance/direction; assessment of heterogen-
eity; process indicators; equity considerations; sustain-
ability of interventions; context; source of funding;
conflict of interest; methodological challenges identified
by authors; comments.
The list of references in the primary studies in the
community pharmacy setting included in the systematic
review was also recorded in this extraction form. Pri-
mary studies were not consulted. We extracted data of
primary community pharmacy studies provided data
were reported in the systematic review in accordance
with guidelines on overviews.
Assessment of methodological quality of included reviews
A threefold critical appraisal of the methodology was
performed as per protocol and further detailed.
Quality of included reviews We used the 16-item
Assessment of Multiple Systematic Reviews (AMSTAR
Costa et al. Systematic Reviews           (2019) 8:272 Page 4 of 20
2) questionnaire to measure the general methodological
quality of each included systematic review [39], assisted
by a general critique on four critical domains considered:
protocol registered before commencement of the review,
adequacy of the literature search, justification for exclud-
ing individual studies, and consideration of risk of bias
when interpreting the results of the review.
Quality of evidence of CP primary studies reported
in reviews We assessed the following: the overall quality
of evidence for deriving effectiveness reported in system-
atic reviews assisted by the Cochrane guidelines “What
study designs should be included in an EPOC review” [40]
and “Suggested Risk of Bias Criteria for Effective Practice
and Organization of Care (EPOC) Reviews” [41]; the qual-
ity of economic evaluations of the studies reported in
systematic reviews assisted by the Consolidated Health
Economic Evaluation Reporting Standards (CHEERS)
checklist [42]; the heterogeneity of populations, interven-
tions, and outcomes, as described by Mossialos et al. [21]
and recommended by CRD for systematic reviews of
public health interventions [34]; and the presence of wider
research issues [9, 34, 36].
Quality assessment of primary studies relies on re-
ported information in included reviews.
Applicability and transferability All systematic reviews
were then collectively assessed in terms of applicability
and transferability of interventions, as described by
Mossialos et al. [21], Wang et al. [43], and CRD and
Cochrane [34–36].
Quality assessment was performed by the lead re-
viewer (SC). Quality of all included reviews, applicability,
and transferability were reviewed by another review
team member (MC). Quality of evidence in eight ran-
domly selected included reviews was reviewed by two
other review team members (CM and DKH). Disagree-
ments were resolved through discussion.
Synthesis of results
Information on study characteristics from systematic
reviews was drawn from the data extraction form and
reported in evidence summary tables. A narrative syn-
thesis was performed, but no additional statistical
analysis was performed. Whenever results described
multiple settings, we limited ourselves to the subset in
the pharmacy setting.
Based on the findings, we proposed a methodological
approach for the measurement and valuation of costs
and health effects and for the types of analysis for
economic evaluations of pharmacy interventions.
Results
Exploratory review of recommendations on the economic
evaluation of public health interventions
First, a systematic review or, at least, an in-depth review
of the best available evidence of the effectiveness and
cost-effectiveness should be performed prior to the
economic evaluation [1, 2]. Second, economic appraisal
should be linked to the appraisal of effectiveness [1, 2,
11, 12]. Third, although individual or cluster randomized
controlled trials (RCTs) are the preferred study design,
they may not always be feasible in the economic evalu-
ation of public health interventions, and randomization
may be difficult, in which case quasi-experimental de-
signs could be an option [2, 11] since few RCTs exist or
are not feasible or appropriate [15, 26–29]. Weatherly
et al. also suggests the use of econometric techniques
[15]. Marsh et al. proposes alternative study designs [27].
Fourth, a societal perspective should be adopted [2, 16].
NICE mentions the public sector’s perspective but
acknowledges the societal perspective, where appropriate
[1]. Fifth, costs and outcomes should be collected during
trial or through decision analytic models but may need
further modeling or estimation procedures based on
links between measurable outcomes and long-term
outcomes [1, 2, 11, 16] reinforced by academic papers
[15, 26, 29]. Sixth, public health interventions tend to
generate broad outcomes, which may not be captured by
quality-adjusted life years (QALYs). Hence, the types of
economic evaluations preferred for public health inter-
ventions are cost-benefit analysis (CBA), to capture
broader health and nonhealth benefits [1, 11, 16], and
cost-consequence analysis (CCA), due to the frequent
nature of multiple outcomes in public health interven-
tions [1, 11]. Cost-utility analysis (CUA) is also required
by NICE whenever health is the sole or predominant
benefit [1]. Both CUA and cost-effectiveness analysis
(CMA) may be used as well [11, 16]. Seventh, academic
papers also report that broad costs and benefits of public
health interventions may fall to nonhealth sectors and
need to be captured in economic evaluations [15, 28,
29]. Weatherly et al. mentions the intersectoral impacts
in CCA and the general equilibrium approach [15]. In
addition to CCA, Weatherly et al. also suggests CBA,
CUA, and multiple-criteria decision analysis (MCDA)
[15]. Lorgelly et al. suggests a capability to encompass
health and nonhealth dimensions [26]. Marsh et al. also
suggests CBA, capabilities, subjective well-being, MCDA,
and better modeling [27]. Eighth, recommended dis-
counting rates for both costs and benefits in economic
evaluations of public health interventions are 1.5% for
NICE [1] and 3% for CDC [16]. Ninth, equity consider-
ations need to be included [1, 2, 11]. Academic papers
also report equity considerations [15, 25, 26, 28, 29].
Cookson et al. suggests possible approaches [25]. Some
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of these approaches were also identified by Lorgelly et al.
and Edwards et al. [26, 28]. Tenth, the economic evalu-
ation of public health interventions should include a wider
spectrum of research methods, including qualitative and
quantitative research, to understand the contextual and
process indicators affecting behavior change [1, 2, 11, 16].
Exploratory review of recommendations for conducting
economic evaluations alongside clinical or pragmatic
trials
First, most authors consider that such economic evalua-
tions should be based on well-designed pragmatic trials
with fewer strict protocols [17, 18]. Second, selection of
subjects and sites should also seek for proximity to real-
world populations [17, 18]. Third, sample size should be
based on important clinical outcomes believed to be
correlated with economic outcomes [17, 18]. Fourth, an
appropriate length of follow-up is required. Estimates
beyond trial time horizon are important and require
good modeling [17, 18]. Fifth, current practice or stand-
ard of care should be the comparator, although there
may be different standards of care in the comparator
[17, 18]. Sixth, outcome measures, if composite, should
be disaggregated, and direct measures are preferred.
Health state utilities should be collected directly from
study subjects at regular intervals by instruments or
mapping techniques [18, 30]. Petrou mentions that
QALYs may sometimes be too restrictive or insensitive
[18]. Seventh, most relevant or economically important
resource use and cost measures should be collected
together with clinical data recorded in case report forms
(CRFs) or patient medical records, patient diaries, and/
or interviews; computerized record linkage may also be
an option in the future [17, 18]. Eighth, valuation in
costs needs to be consistent with resource use, perspec-
tive, and time horizon. It may include microcosting, unit
costing, and gross costing [17, 18]. Ninth, papers outline
several additional recommendations concerning methods:
plan of statistical analysis and hypothesis prior to trial;
plan for on-going data quality monitoring; incremental
analysis with an intention-to-treat approach; common
time horizon for costs and outcomes; within-trial assess-
ment of costs and outcomes; arithmetic mean cost differ-
ences for cost comparisons and bootstrapping, OLS or
GLM to compare difference between groups; multivariable
methods for analysis of outcomes; uncertainty through
confidence intervals, p values, and incremental cost-
effectiveness ratios (ICERs) on various time horizons;
common discount rate; accounting for missing/censored
data through imputation of missing data using multiple
imputation approaches; and one or more summary
measures (ratio, difference, and/or probability measures)
[18, 30]. Tenth, Ramsey and Petrou mention that report-
ing should include the following: description of trial;
major findings; economic data collected; missing and
censored data; methods to project costs and outcomes;
statistical methods; resource use, costs and outcomes; and
results within and beyond time horizon of trial [18, 30].
Overview of systematic reviews of economic evaluations
of pharmacy interventions
Study selection
Electronic searches until July 2017 identified 761 potential
citations, of which 45 duplicates were found and removed,
leaving 716 potential titles. The initial title screening
excluded 594 (588 not matching inclusion criteria, 4
duplicates, and 2 protocols) titles, leaving a total of 122
potentially relevant titles. Abstract assessment resulted in
the further exclusion of 100 studies and 22 potentially
relevant abstracts were retrieved. The full-text assessment
process resulted in 14 articles being retrieved.
OpenGrey and ISPOR Databases returned 1 and 77
potential titles, respectively, but all were excluded after
abstract assessment. Hence, no references were obtained
from gray literature.
Snowballing did not identify further reviews. A total of
14 reviews were included [24, 44–56].
PROSPERO registry returned 28 potential titles of ongoing
reviews which were excluded after abstract assessment.
Figure 1 illustrates the study selection process.
Description of included reviews
Fourteen systematic reviews containing 118 included
publications (including double counting) corresponding
to 75 index publications on economic evaluation in
community pharmacy were included.
A CCA value of 4.4% was obtained, indicating only a
slight degree of overlap.
Characteristics of included reviews Search dates of
systematic reviews range from 1988 to 2015 (28 years).
Reviews were published in 11 different journals: 5 phar-
macy journals (Pharmacotherapy, American Journal of
Health-System Pharmacists, Journal of Managed Care Phar-
macy, Journal of Clinical Pharmacy and Therapeutics, An-
nals of Pharmacotherapy); 2 health journals (BMJ Open,
Health Policy); 2 pharmacoeconomic journals (Pharmacoe-
conomics, Expert Review of Pharmacoeconomics & Out-
comes Research); and 2 disease-specific journals (Diabetic
Medicine, Hellenic Journal of Cardiology).
Only two reviews exclusively focused on both economic
evaluation studies and the community pharmacy setting
[53, 55]. Economic evaluation studies in community phar-
macy represented 87.5% of studies in Altowaijiri et al.
[49], 71% in Gammie et al. [56], 45% in Elliot et al. [24],
and 40% in Wang et al. [51].
Reviews contain studies from 12 different countries, of
which 7 are from Europe. The origin of studies in
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reviews published until 2013 was mostly the USA and
other countries outside of Europe. After 2014, we see an
increase in the proportion of studies from Europe.
With a few exceptions [49, 51, 52, 54], most reviews
tend to include studies addressing all very diverse
populations, interventions, and outcomes. Populations
do not seem to be well detailed.
Eight reviews allowed randomized trials, nonrandomized
trials, and other controlled designs. Only 3 reviews reported
RCT as inclusion criteria for included studies [49, 54, 55].
Fig. 1 Study selection process
Costa et al. Systematic Reviews           (2019) 8:272 Page 7 of 20
Table 1 summarizes the characteristics of included
reviews.
Economic findings of included reviews Most reviews
report medication costs, supplies/tests costs, and health-
care utilization costs. More recent reviews also report in-
direct costs. Very few reviews report intervention costs
charged.
Only half of the reviews report cost year and discount
rates of included studies. Nine reviews report the per-
spectives of included studies.
Almost all reviews include trial-based studies. Four re-
views also report synthesis/model-based studies.
Summary measures, namely, incremental ratios, are re-
ported in eight recent reviews. Five reviews report
benefit-to-cost ratio as a summary measure.
Six reviews report uncertainty of included studies but
only two of them explicit sensitivity analysis methods
[24, 53].
Table 2 summarizes the major economic findings of
included reviews.
Description of community pharmacy (CP) primary studies
reported in reviews
Nearly 60% of CP primary studies (index publications)
are from the USA and the UK.
Figure 2 illustrates countries of origin of economic
evaluation of community pharmacy primary studies.
Disease management is the most frequent intervention
category in primary studies (40 studies), namely, in dia-
betes, hypertension, hyperlipidemia, asthma, and smok-
ing cessation, followed by medication management (13
studies) and high cost/case management, especially for
the elderly on multiple medication (10 studies). Adher-
ence is the intervention category in 5 studies for patients
new to therapy, screening in 4 studies, and disease pre-
vention (immunization) in 2 studies. The intervention
for one study was not reported.
Thirty-one studies are controlled trials. Seven studies
are nonrandomized trials, and one is a multiple inter-
rupted series design. Twelve studies (16%) are model
counterfactual. Twelve studies are reported as not con-
trolled, 3 are nonconcurrent cohort studies, 2 are be-
fore/after designs, 1 is a retrospective cohort study, and
no report exists for 6 studies.
CEA is the most frequent type of economic analysis,
followed by CUA. However, 19 studies are not full eco-
nomic analyses (Fig. 3).
Health payer is the most frequent perspective reported
(43 studies), societal perspective is reported for 8 studies,
2 studies seem to adopt both payer and societal perspec-
tives, and provider perspective is reported for 6 studies.
The perspective is not reported in reviews for 16 studies.
When reported, the time horizon most frequently re-
ported is up to 12 months. Sensitivity or scenario ana-
lysis is reported for 19 studies, currency year for 50, and
discount rate for 6 studies only (3%, 3.5%, and 4%), of
which 2 studies present lower discount rates for conse-
quences (1.5%). Summary measures are reported for 27
studies, 16 of which are ICERs.
Overall, reviews reported favorable economic findings
for 37 of 52 studies (71%) with full economic evaluations
or CCA or cost-minimization analysis (CMA).
See supplementary characteristics of primary studies
as reported in included reviews, Additional file 4.
Methodological quality of included reviews
Quality of included reviews In accordance with recom-
mended approach in AMSTAR 2, we identified (four) critical
domains; we assessed all 16 items for each included review
but did not use responses to derive an overall score; and we
rated overall confidence on the four critical domains as high
(green), moderate (yellow), or low (red). The two critical
quality domains that seem to be absent from almost all re-
views are protocol registered before commencement of the
review and no justification for excluding individual studies.
Table 3 summarizes the results of quality assessment
of included reviews in the considered four critical do-
mains of AMSTAR 2.
See supplementary complete quality assessment of in-
cluded reviews in all 16 items of AMSTAR, Additional file 5.
Quality of evidence of CP primary studies reported
in reviews We assessed the quality of evidence of CP pri-
mary studies reported in Reviews in five areas: quality of
evidence for deriving effectiveness; risk of bias; quality of
economic evaluation; heterogeneity; wider research issues.
Quality of evidence of CP primary studies for deriving
effectiveness. Three reviews defined RCTs as one inclu-
sion criteria [49, 54, 55]. Three others used an instrument
to assess the quality of included study designs [24, 47, 50].
Chisholm-Burns et al. used a simple hierarchy of study de-
signs, Elliot et al. used Standard Hierarchies of Evidence
[57], and Brown et al. used Cochrane’s Effective Practice
and Organization of Care (EPOC) study design criteria
[40]. Thirty-nine of 57 reported trial-based studies (68%)
used an EPOC review recommended study design.
Risk of bias of CP primary studies. Three recent re-
views used an instrument to assess the risk of bias of in-
cluded studies [50, 54, 55].
Brown et al. used the six-item Effective Public Health
Practice Project Quality Assessment Tool for Quantita-
tive Studies [58]. This review included randomized and
nonrandomized trials. Six studies were rated “strong,”
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four studies were rated “moderate,” and nine studies
were rated “weak.”
Loh et al. used the seven-item Cochrane Collabora-
tion’s tool for assessing risk of bias in randomized trials
[59]. Selection bias (random allocation and allocation
concealment) was the highest risk rated. However, low
risk of bias represented more than 50% of items scored
in all studies except one.
Malet-Larrea et al. used the nine-item Risk of Bias for
EPOC Reviews Tool [41]. This review included random-
ized trials only. Seven studies were rated high risk, four
were rated medium risk, and two were rated low risk.
Risk of contamination and not reporting baseline char-
acteristics of providers were the highest risks rated.
Six reviews used no instrument but reported risk of bias
in included studies [24, 45, 46, 48, 51, 53]. Assisted by the
Risk of Bias for EPOC Reviews Tool, we identified random
sequence generation, allocation concealment, baseline
characteristics, baseline outcome measurements, and pro-
tection against contamination as the most frequent items
reported for higher risk of bias in these reviews.
One review assessed but reported no significant bias [56].
Four reviews did not assess risk of bias [44, 47, 49, 52].
Quality of economic evaluation of CP primary studies.
Five reviews used an instrument to assess the quality of eco-
nomic evaluations of included studies [24, 46, 48, 51, 55].
Perez et al. used an instrument developed by the
authors [46]. Touchette et al. used the Quality of
Health Economic Studies (QHES) for the total 18 full
economic evaluations [48]. The first review to use
CHEERS was Elliot’s [24]. Worst performance criteria
seem to be the following: contamination between
intervention and comparator, costs incurred by
patient, indirect costs, discounting, accounting for un-
certainty, summary measures, and sensitivity or sce-
nario analyses.
Wang et al. also used CHEERS [51]. The authors re-
ported that many of the studies met most CHEERS
criteria despite some issues in presenting summary mea-
sures, in dealing with uncertainty and with impact of
heterogeneity.
Fig. 2 Countries of origin of economic evaluation of community pharmacy primary studies
Fig. 3 Types of economic analysis of economic evaluation CP primary studies
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Malet-Larrea et al. used the Evers Checklist Tool used
for all economic evaluations in addition to the Phillips
instrument for three combined trial and model-based
economic evaluations [55]. The authors also reported a
high quality in eight studies, medium quality in three
studies, and low quality in two studies.
Six other reviews did not use an instrument but per-
formed some assessment of economic evaluation in the
included studies [44, 45, 47, 49, 53, 56]. Assisted by
CHEERS, we identified criteria that present some issues
based on reported data of primary studies in reviews:
not detailing characteristics of target population; not de-
scribing “usual care” comparators; not including patient
costs, indirect costs or intervention fees; analytical
methods poorly described; incremental costs and out-
comes sometimes not reported; not accounting for un-
certainty; issues in characterizing heterogeneity; and not
reporting the source of funding of studies.
Heterogeneity (populations, interventions, outcomes)
of CP primary studies. Ten reviews include studies ad-
dressing diverse populations, interventions, outcomes,
and even settings, and most report this variability, which
does not allow synthesizing results or generalizing [24,
44–46, 48–51, 53, 55].
Four reviews do not assess or report the impact of het-
erogeneity in results [47, 52, 54, 56].
Wider research issues of CP primary studies.
Twelve reviews do not report equity considerations—
e.g., whether socioeconomic variables had differential
effect on intervention—an important aspect in public
health interventions [24, 44–46, 48, 49, 51–56].
Nine reviews provide some meager considerations on the
sustainability of interventions [24, 45, 46, 48, 50, 52, 53, 55,
56]. However, most of these are restricted to training of
staff and integration into routine and provide no informa-
tion on the economic and political variables to understand
its impact on sustainability. Five reviews do not report any
assessment of sustainability [44, 47, 49, 51, 54].
Eight reviews provide some considerations on the
context of the included studies [46, 48, 50–53, 55, 56].
US reviews focus on framework legislation encour-
aging added value interventions while European
reviews tend to address context barriers, including
lack of funding for cost-effective interventions. Six re-
views, however, do not address the context of included
studies [24, 44, 45, 47, 49, 54].
Applicability and transferability Assisted by Wang’s
framework, nine reviews briefly discuss the importance
of process dimensions for applicability: political environ-
ment, resource implications, and organizational struc-
ture of pharmacies and skill of pharmacists. The social
acceptability by the target population, cultural adaptabil-
ity, and the impact of the educational level of the target
population are not reported in reviews.
Reviews do not seem to discuss the importance of the
following outcome dimensions for transferability: base-
line prevalence of the condition, differences in popula-
tions, and capacity to implement the intervention.
However, despite variations in populations and in the
capacity to implement the intervention, we observe some
consistency in favorable findings for some intervention
categories across different countries.
Synthesis of results
Economic evaluations of pharmacy-based public health in-
terventions include various elements, additional dimen-
sions, and challenges which are summarized in Table 4.
Favorable economic findings appear for 71% of studies
with full economic evaluations or CCA or CMA.
In triangulation with recommendations for economic
evaluations of both public health interventions and
alongside trials, we assessed all ten items of these recom-
mendations for each included review and we rated
collective overall agreement of reviews with each item as
high (green), moderate (yellow), or low (red).
Triangulation with recommendations for economic
evaluations both of public health interventions and
alongside trials reveals poor evidence of the following:
societal perspective, costs and benefits falling on non-
health sectors, lower discounting rates (vs medicines),
equity assessment, valuation of costs, and methods for
costs and outcome analysis.
The following recommendations are present but not
well detailed: prior review of evidence, linking intermedi-
ate to long-term outcomes, wider spectrum of research
Table 3 Quality of included reviews in critical domains (AMSTAR 2)
No. AMSTAR 2 item n (%) Critical domains
2 Explicit statement—review methods established prior to review and justification
for deviations from protocol
2 (14%)
4 Used comprehensive literature search strategy 14 (100%)
7 Provided list of excluded studies and justification for exclusions 0 (0%)
13 Accounted for risk of bias in individual studies when interpreting/discussing
results of review
10 (71%)
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methods, selection of subjects and sites seeking real-world
target population and providers, current practice or stand-
ard of care, cost data collection, and detailed reporting.
In contrast, the following recommendations are usu-
ally present and well detailed: economic appraisal is
linked to effectiveness, most study designs are RCTs but
include other controlled designs, the types of economic
evaluation are diverse, study designs tend to be prag-
matic, sample size is based on an important clinical out-
come correlated with economic outcomes, and single
direct measures are usually preferred.




Economic evaluations of pharmacy-based public health in-
terventions seem to follow most economic quality criteria,
but there are still some issues in certain key areas to
improve.
This overview sought to include all relevant systematic
reviews complying with inclusion criteria, with no re-
strictions on the period covered, populations, interven-
tions, comparators, or outcomes, in attempt to be
inclusive and to critique methods.
We have defined four of seven AMSTAR 2 critical
domains for an overall critique on how well included
Table 5 Triangulation with key recommendations on the economic evaluation of public health interventions
# Key recommendations Overview findings
1 Review of evidence:
Systematic review or in-depth review of evidence prior to the economic evaluation
of PHI
2 Effectiveness and economic appraisal:
Economic appraisal linked to the appraisal of effectiveness of PHI
3 Study designs:
When randomized trial not feasible, quasi-experimental designs or econometric
techniques
4 Perspective:
Societal perspective (public sector may be used where appropriate)
5 Time horizon:
Trial data may need modeling but requires reliable link between intermediate and long-
term outcomes
6 Types of economic evaluation preferred:
CBA and CCA preferred but CUA and CEA also recommended whenever health is the
sole benefit
7 Nonhealth costs and benefits of PHI:
Need to capture costs and benefits falling on nonhealth sectors
8 Discounting rates:
Lower discounting rates for PHI (1.5% for NICE, 3% for CDC) if costs and health effects
accrued > 1 year
9 Equity considerations:
Compare differences in health status changes between different health economic groups
10 Wider spectrum of research methods:
Understand contextual and process indicators affecting behavior change and other variables
PHI public health interventions, CBA cost-benefit analysis, CCA cost-consequence analysis, CUA cost-utility analysis, CEA cost-effectiveness analysis, NICE National
Institute for Health and Care Excellence, CDC Centers for Disease Control and Prevention
Table 4 Major key methodological findings
Most frequent risk of
biases
Random sequence generation, allocation concealment, baseline characteristics, baseline outcome measurements similar, and
contamination between intervention and comparator
Study designs Not restricted to RCTs or cluster RCTs
Economic quality
criteria
Most criteria are met but there are some issues: not detailing target population; not describing “usual care” comparators; not
including patient costs, indirect costs or intervention fees; analytical methods poorly described; incremental costs and
outcomes sometimes not reported; not accounting for uncertainty
Heterogeneity In populations, interventions and some outcomes
Equity Not assessed
Process dimensions Process dimensions that impact dissemination and external validity poorly described.
RCT randomized controlled trial
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reviews performed in these domains, as recommended.
Risk of bias from individual studies being included in
the review was not considered, since the most important
instruments for nonrandomized studies included in a
systematic review were released in 2016 and 2017.
Appropriateness of meta-analytical methods was not
considered, since included reviews were narrative.
Assessment of presence and likely impact of publication
bias was also not considered, since funnel plot asym-
metry requires a minimum of ten studies and included
reviews each have eight studies on average.
The findings of this overview are consistent with
methodological issues described by Elliot et al., Perrau-
din et al., Malet-Larrea et al., Jommy, and Whitty for
the economic evaluation of pharmacy-based interven-
tions [24, 53, 55, 60, 61]. In addition, they are also
consistent with the major methodological challenges
described by Weatherly et al. for the economic evalu-
ation of public health interventions [15] and with the
methodological challenges described by O’Sullivan et al.
for the economic evaluation conducted alongside
clinical trials [17].
Limitations
This review only included those studies containing the
selected search terms. Hence, it is possible we might
have missed relevant systematic reviews that may have
used a different terminology.
We used a specific filter recommended by the Centre
for Reviews and Dissemination (CRD) for economic evalu-
ation in Embase via Ovid, as stated in Additional file 2.
We did not find a specific filter for economic evalu-
ation for other databases used in this review published
in ISSG Search Filter Resource. We restricted the search
strategy to the definition of full economic evaluation,
that is, comparing costs and health outcomes of two or
more interventions in which three generic types of
economic evaluation are used: cost-effectiveness, cost-
utility, or cost-benefit analyses. We deliberately excluded
search terms used in partial economic evaluations. How-
ever, this restriction might have implicated on the sensi-
tivity of these searches.
In addition, it is possible we might have missed rele-
vant recommendations on economic evaluations of
public health interventions and/or alongside trials due
Table 6 Triangulation with key recommendations on the economic evaluation alongside clinical or pragmatic trials
# Key recommendations Overview findings
1 Study design:
Based on well-designed pragmatic/naturalistic trials with fewer strict protocols
2 Selection of subjects and sites:
Seek for proximity to real-world target population and less restrictive patient
inclusion criteria
3 Sample size:
Based on important clinical outcome correlated with economic outcome,
previous pilot or wider CI for ICER/CEAC
4 Estimates beyond trial:
Appropriate length of follow-up, estimates beyond trial require survival analysis,
link to final outcomes or regression
5 Comparator:
Current practice or standard of care should be the comparator, although there
may be different standards of care
6 Measures of outcomes:
Direct, single measures are preferred. Utilities collected directly from study subjects
at regular intervals
7 Data collection (resource use and costs):
Relevant resource use and cost measures collected with clinical data (case report
forms, patient records, patient diaries, interviews, computerized record linkage)
8 Valuation of costs:
May include: microcosting; unit costing; and gross costing
9 Methods for cost and outcome analysis:
Arithmetic mean cost differences, bootstrapping, OLS or GLM for between group
comparison; multivariable methods for outcomes; confidence intervals, p values, ICERs
on various time horizons; summary measures
10 Reporting:
General description of trial and major findings; economic data collected alongside trial;
missing and censored data; methods to construct, compare and project costs and
outcomes; statistical methods; results on resource use, costs and outcomes; results within
and beyond time horizon of trial.
CI confidence intervals, ICER incremental cost-effectiveness ratio, CEAC cost-effectiveness acceptability curve
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to the selected exploratory approach used for these re-
views with the sole purpose of obtaining key insights
for triangulation.
Conclusions
Implications for practice and policy
In recent years, governments in various countries have in-
troduced profound changes to pharmacy remuneration sys-
tems in the components related to equitable, safe, and
quality access to medicines and to efficiency and/or quality
incentives. These two components are the most important
in pharmacy remuneration systems. However, the network
of pharmacies provides a unique opportunity for govern-
ments to implement relevant public health interventions,
that fit within national, regional and local health policies, in
close collaboration with primary care. In several countries,
governments have already contracted with pharmacies to
pay for relevant interventions. However, as for any other
health technology, public health interventions provided by
community pharmacists must seek to demonstrate effect-
iveness and economic benefits to be reimbursed by public
payers.
The economic evaluation of pharmacy interventions
presents challenges.
We hope the findings of this overview may assist in
improving the design, implementation, and assessment
of pilot trials; hence, the robustness of evidence to
justify payers’ investment, which requires the endorse-
ment of community pharmacists to participate in tri-
als and an informed understanding of policy makers
in negotiations.
Implications for research
Based on the findings of this overview and in addition to
the methodological considerations for economic evalua-
tions of pharmacist interventions by Elliot et al. [24], we
propose a methodological approach for the economic
evaluation of pharmacy-based public health interven-
tions (see Table 7).
As the research corpus continues to expand following
practice and policy requirements, it will become import-
ant to build a multidisciplinary expert consensus around
a specific guidance for the economic evaluation of
pharmacy-based public health interventions.
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